Periodic Reporting for period 3 - SPHERES (Lipid droplet hypertrophy : the link between adipocyte dysfunction and cardiometabolic diseases)
Reporting period: 2023-09-01 to 2025-02-28
Using advanced scientific tools, SPHERES has made key discoveries. Researchers have identified how specific proteins (PLIN isoforms) associate to different lipid droplets according the speed at which they form. They’ve also shown that a key enzyme, hormone-sensitive lipase (HSL), has vital roles in fat development beyond breaking down fat. Other breakthroughs include understanding short-chain triglycerides (a type of fat) and their quick breakdown in cells, as well as the importance of fat breakdown in brown fat for heat production.
Additionally, SPHERES discovered unique enzymes, and developed long-lasting fat cell precursors that improve fat cell studies. By unraveling these mechanisms, SPHERES is paving the way for innovative treatments to improve metabolic health, reduce disease rates, and lessen the global burden of these chronic conditions.
Key achievements include creating the Lipid Droplet Knowledge and Adipose Tissue Knowledge Portals, two central resources for LD and adipose tissue data, and applying CRISPR/Cas9 gene editing to produce precise models for studying adipose biology. The team identified distinct subtypes of white adipocytes with unique insulin responses, highlighting the complexity of adipose tissue and its impact on metabolic health. Proteomic and imaging advances have mapped molecular networks within fat cells, while studies clarified how perilipin proteins (PLINs) regulate LD stability and function.
Research also revealed that hormone-sensitive lipase (HSL) plays essential roles beyond fat breakdown, particularly in fat tissue development, using innovative knockout models. Explorations of short-chain triglycerides (TGs) uncovered their rapid breakdown at LD surfaces, which influences cellular metabolism. In brown fat, studies showed that intracellular fat breakdown is vital for heat production, identifying therapeutic targets for metabolic diseases.
Additionally, SPHERES discovered PLCXD1, a novel enzyme involved in adipocyte metabolism, and developed immortalized CD55+ precursor cells for advanced studies of adipocyte diversity. Together, these breakthroughs pave the way for new treatments targeting obesity, diabetes, and related conditions, demonstrating SPHERES’ potential to bridge science and clinical care.